Are You Getting the Most Specific and Consistent Data from Your Protein Microarrays?

Find out how Sengenics can take your autoantibody biomarker program to the next level

Sengenics patented KREX protein folding technology ensures all array proteins are correctly folded, full-length and functional resulting in exceptional binding specificity and inter- & intra-array reproducibility.

Biomarker Discovery

Identification of autoantibody biomarker signatures

Response Prediction

Predict responders, non-responders and those at risk for adverse events

Patient Stratification

Intra-disease stratification, identification of cohorts and clinical trial patient enrichment

CDx Development

Establish biomarker signatures for companion diagnostic development

Cancer Prediction

Unique differential profiling of cancer-antigens in various cancer types

biologically meaningful hits and
actionable data

Discover how our highly specific protein arrays translates to more accurate results

View our KREX technology in action

Sengenics Off-the-Shelf and Custom Protein Microarrays

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389